Why are ampicillin and amoxicillin often co-formulated with clavulanate in clinical products?

Because clavulanate competitively inhibits human serum proteases that would otherwise inactivate amoxicillin systemically, thereby increasing systemic half-life rather than targeting bacterial resistance enzymes.

Because clavulanate acts as a membrane-permeabilizing agent that widens all porins, allowing ampicillin and amoxicillin to reach intracellular targets even in organisms that lack the necessary PBPs.

Because clavulanate chelates divalent ions required for peptidoglycan cross-linking, acting synergistically with ampicillin by independently blocking PBP active sites and eliminating the need to inhibit beta-lactamases.

Because the amino-group modifications enable these drugs to pass Gram-negative porins and reach PBPs, but they remain vulnerable to many beta-lactamases; clavulanate inhibits those enzymes, restoring antibiotic efficacy.